NCT00304278 - Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

May 31, 2015

Study Completion Date

December 31, 2015

Conditions

Head and Neck Cancer

Interventions

DRUG

Erlotinib (Tarceva)

150 mg daily X 7 weeks

DRUG

Intra-arterial Cisplatin (PLAT)

1 dose (150 mg/sq) per week X 4 weeks

RADIATION

Radiation Therapy (RAD)

5 days per week X 7 weeks

Trial Locations (1)

Simmons Cooper Cancer Institute/SIU School of Medicine, Springfield